---
title: "Carisma Therapeutics On June 26, Notified Novartis Pharmaceuticals Of Termination Of Co's Manufacturing & Supply Agreement Between Co & Novartis"
description: "Carisma Therapeutics has terminated its manufacturing and supply agreement with Novartis Pharmaceuticals, effective July 31, 2024. The company will now focus on its follow-on product candidate CT-0525"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/207818143.md"
published_at: "2024-07-02T21:01:51.000Z"
---

# Carisma Therapeutics On June 26, Notified Novartis Pharmaceuticals Of Termination Of Co's Manufacturing & Supply Agreement Between Co & Novartis

> Carisma Therapeutics has terminated its manufacturing and supply agreement with Novartis Pharmaceuticals, effective July 31, 2024. The company will now focus on its follow-on product candidate CT-0525 for ex vivo oncology clinical development. Enrollment of new patients in its phase 1 clinical trial for CT-0508 has been suspended.

July 2 (Reuters) - Carisma Therapeutics Inc (CARM.O) :

-   CARISMA THERAPEUTICS : ON JUNE 26, NOTIFIED NOVARTIS PHARMACEUTICALS OF TERMINATION OF CO’S MANUFACTURING & SUPPLY AGREEMENT BETWEEN CO & NOVARTIS
    
-   CARISMA THERAPEUTICS INC - TERMINATION OF CO’S MANUFACTURING AND SUPPLY AGREEMENT, BY AND BETWEEN CO AND NOVARTIS IS EFFECTIVE JULY 31, 2024
    
-   CARISMA THERAPEUTICS - CO DETERMINED TO FOCUS EX VIVO ONCOLOGY CLINICAL DEVELOPMENT EFFORTS ON ITS FOLLOW-ON PRODUCT CANDIDATE CT-0525
    
-   CARISMA THERAPEUTICS INC - HAS SUSPENDED ENROLLMENT OF NEW PATIENTS IN ITS PHASE 1 CLINICAL TRIAL FOR CT-0508

### Related Stocks

- [CARM.US - Carisma Therapeutics](https://longbridge.com/en/quote/CARM.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Carisma Therapeutics Announces Separation Agreements with CEO and CSO, Detailing Severance and Pro-Rated Bonuses Amid Wind Down | Carisma Therapeutics Inc. has announced separation agreements for its CEO Steven Kelly and CSO Michael Klichinsky as the | [Link](https://longbridge.com/en/news/261316519.md) |
| Carisma Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview | Carisma Therapeutics Inc is anticipated to report a loss of 12 cents per share for the quarter ending September 30, 2025 | [Link](https://longbridge.com/en/news/264052760.md) |
| Carisma Therapeutics Amends Agreement with Moderna, Receives $4 Million Payment | Carisma Therapeutics Inc. has amended its Collaboration and License Agreement with ModernaTX, Inc., effective September  | [Link](https://longbridge.com/en/news/257933444.md) |
| Carisma Therapeutics Delists Common Stock | Carisma Therapeutics Inc. has filed to deregister its common stock, terminating its reporting obligations as a public co | [Link](https://longbridge.com/en/news/270996498.md) |
| Ocugen Inc. Announces Termination of Merger Agreement with Carisma Therapeutics Due to Funding Shortfall | Ocugen Inc. has terminated its merger agreement with Carisma Therapeutics due to a funding shortfall. The merger, initia | [Link](https://longbridge.com/en/news/257950392.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.